Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025
Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1 The real catalyst comes from Roche. Roche’s giredestrant delivers a landmark Phase 3 win Roche’s Genentech unit announced that giredestrant, its investigational oral selective estrogen receptor degrader (SERD), hit the primary endpoint in the Phase 3 lidERA trial in early-stage ER+/HER2- breast cancer. RTT News+1 Key points from today’s breast cancer data: For Olema, none of that is its own data — but it’s